ZURA
NASDAQ · Biotechnology
Zura Bio Ltd
$4.80
+0.05 (+1.05%)
Open$4.66
Previous Close$4.75
Day High$4.82
Day Low$4.63
52W High$7.44
52W Low$0.98
Volume—
Avg Volume700.0K
Market Cap458.84M
P/E Ratio—
EPS$-0.75
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+381.7% upside
Current
$4.80
$4.80
Target
$23.12
$23.12
$15.51
$23.12 avg
$31.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 178.15M | 170.40M | 174.38M |
| Net Income | 4.79M | 4.86M | 5.73M |
| Profit Margin | 2.7% | 2.9% | 3.3% |
| EBITDA | 8.96M | 8.92M | 9.38M |
| Free Cash Flow | 5.34M | 5.40M | 5.82M |
| Rev Growth | +24.5% | +6.4% | +20.2% |
| Debt/Equity | 0.26 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |